Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer

Zacho, Helle D; Nielsen, Jesper; Afshar‐Oromieh, Ali; Haberkorn, Uwe; deSouza, Nandita M.; Paepe, Katja De; Dettmann, Katja; Langkilde, Niels Christian; Haarmark, Christian; Fisker, Rune Vincents; Arp, Dennis Tideman; Carl, Jesper; Jensen, Jørgen Bjerggaard; Petersen, Lars Jelstrup

doi:10.1007/s00259-018-4058-4

Cited by 79 publications

(67 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study of 123 patients with relapsed PCa, PSMA-PET showed a higher detection rate than choline-PET/CT for bone lesions (98 vs. 64%), even though ultimately there were mismatches for both tracers (41). PSMA-PET/CT and 18FNa-PET/CT methods were comparable and performed significantly better than DW600-MRI, which was less adequate for diagnosing bone metastases when conducted in accordance with the European Society of Urogenital Radiology guidelines (48).…”

Section: Is There Bone Disease?mentioning

confidence: 98%

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

et al. 2020

View full text Add to dashboard Cite

Background: Initial staging and assessment of treatment activity in metastatic prostate cancer (PCa) patients is controversial. Indications for the various available imaging modalities are not well-established due to rapid advancements in imaging and treatment. Methods:We conducted a critical literature review of the main imaging abnormalities that suggest a diagnosis of metastasis in localized and locally advanced PCa or in cases of biological relapse. We also assessed the role of the various imaging modalities available in routine clinical practice for the detection of metastases and response to treatment in metastatic PCa patients. Results:In published clinical trials, the most commonly used imaging modalities for the detection and evaluation of therapeutic response are bone scan, abdominopelvic computed tomography (CT), and pelvic and bone magnetic resonance imaging (MRI). For the detection and follow-up of metastases during treatment, modern imaging techniques i.e., choline-positron emission tomography (PET), fluciclovine-PET, or Prostate-specific membrane antigen (PSMA)-PET provide better sensitivity and specificity. This is particularly the case of fluciclovine-PET and PSMA-PET in cases of biochemical recurrence with low values of prostate specific antigen. Conclusions:In routine clinical practice, conventional imaging still have a role, and communication between imagers and clinicians should be encouraged. Present and future clinical trials should use modern imaging methods to clarify their usage. Inclusion and Exclusion CriteriaOnly original manuscripts and reviews published in indexed and peer-reviewed journals and written in English between August 1999 and December 2019 were considered. Cross-sectional studies, case reports, published abstracts, dissertation materials, and conference presentations were excluded. Of 1,725 potential articles from the literature search, 105 were selected, including 16 literature reviews, 5 meta-analyses, 11 guidelines or position papers, and 73 original articles.

show abstract

Section: Is There Bone Disease?mentioning

confidence: 98%

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The diagnostic performances of NaF, FCH and DW-MRI in this setting have already been published [7,9,30,31]. The accuracy of NaF in detecting bone metastases was found to be significantly better than that of DW-MRI in a recent prospective comparison of 68 PCa patients with BCR [7]. Langsteger et al observed a better lesion-based specificity of FCH compared to that of NaF (96% vs 91%, p = 0.033) for an equivalent sensitivity of 89% in the context of BCR [9].…”

Section: Imaging Performancesmentioning

confidence: 99%

“…18 F-sodium fluoride positron emission tomography/ computed tomography (PET/CT) (NaF), 18 F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) are three novel imaging techniques that are effective for the detection of PCa bone metastases and their results may impact the management of patients [6]. Their diagnostic performances in detecting bone metastases in PCa patients with first biochemical recurrence (BCR) have already been published [7][8][9]. However, to the best of our knowledge, their cost-effectiveness in this indication has never been compared.…”

Section: Introductionmentioning

confidence: 99%

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

et al. 2020

View full text Add to dashboard Cite

Background: The diagnostic performance of 18 F-sodium fluoride positron emission tomography/computed tomography (PET/CT) (NaF), 18 F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared. Methods: We performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule. Results: There was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental costeffectiveness ratio of 3000€/QALY when imaging was interpreted by local specialists and 9000€/QALY when imaging was interpreted by experts. Conclusions: FCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.

show abstract

“…This white paper comprises consensus recommendations on performance, quality standards, and reporting of WB MRI to accommodate the increased use of WB MRI. Of note, the current literature suggests that WB MRI may be less sensitive to current PET technologies for detection of PCa (8,9); however, more robust data are needed, particularly to evaluate a possible complementary role for MR and PET.…”

Section: Overview Of Available Imaging Modalities Mrimentioning

confidence: 99%

Multimodality Imaging of Prostate Cancer

2019

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the various distinct clinical scenarios for prostate cancer; (2) the various imaging modalities available for use in prostate cancer; (3) the role of these imaging modalities in primary or recurrent prostate cancer and their advantages and disadvantages; and (4) the future potential of theranostic approaches and the evolving indications for contemporary hybrid imaging modalities such as PET/MRI and whole-body MRI. Financial Disclosure: Dr. Burger has received research grants and speaker honorarium from GE Healthcare. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through October 2022. Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors. In recent years, imaging has gained increasing importance in the detection, staging, posttreatment assessment, and detection of recurrence of prostate cancer. Several imaging modalities including conventional and functional methods are used in different clinical scenarios with their very own advantages and limitations. This continuing medical education article provides an overview of available imaging modalities currently in use for prostate cancer followed by a more specific section on the value of these different imaging modalities in distinct clinical scenarios, ranging from initial diagnosis to advanced, metastatic castration-resistant prostate cancer. In addition to established imaging indications, we will highlight some potential future applications of contemporary imaging modalities in prostate cancer.

show abstract

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer

Cited by 79 publications

References 39 publications

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Multimodality Imaging of Prostate Cancer

Contact Info

Product

Resources

About